Immune cells engineered to seek out and attack a type of deadly brain cancer known as glioblastoma (GBM) were found to have an acceptable safety profile and successfully migrate to and infiltrate tumors, researchers from Penn Medicine and Harvard University reported at the AACR Annual Meeting 2016. Department members Drs. MacLean P. Nasrallah, Jennifer Morrissette, Maria Martinez-Lage, Bruce Levine, and Carl June were co-authors of the clinical trial study.
Read the Department of Communications news release.